Clin Colon Rectal Surg 2018; 31(03): 168-178
DOI: 10.1055/s-0037-1602237
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Colorectal Cancer in Inflammatory Bowel Disease

Ryan W. Stidham
1   Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
Peter D.R. Higgins
1   Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
01 April 2018 (online)


Patients with inflammatory bowel disease (IBD) are at significantly increased risk of colorectal cancer (CRC), principally resulting from the pro-neoplastic effects of chronic intestinal inflammation. Epidemiologic studies continue to highlight the increased risk of CRC in IBD. However, the incidence has declined over the past 30 years, attributed to both successful CRC-surveillance programs and improved control of mucosal inflammation. Risk factors that further increase the risk of IBD-related CRC include disease duration, extent and severity, the presence of inflammatory pseudopolyps, coexistent primary sclerosing cholangitis, and a family history of CRC. All major professional societies agree that IBD-CRC surveillance should occur more frequently than in the general population. Yet, guidelines and consensus statements differ on the surveillance schedule and preferred method of surveillance. Improved sensitivity to previously “invisible” flat dysplastic lesions using high definition and chromoendoscopy methods has resulted in many guidelines abandoning requirements for random untargeted biopsies of the colon. While colonic dysplasia remains a worrisome finding, and several clinical scenarios remain best addressed by total proctocolectomy due to concerns of synchronous undetected lesions and the unpredictable tempo of progression to malignancy, better detection techniques have also increased opportunities for endoscopic resection of dysplastic lesions that can be clearly delineated. Finally, the expanding armamentarium of medical options in IBD, including anti-tumor necrosis factor and anti-adhesion biologic therapies, have substantially improved our ability to control severe inflammation and likely reduce the risk of CRC over time.

  • References

  • 1 Wanders LK, Dekker E, Pullens B, Bassett P, Travis SPL, East JE. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2014; 12 (05) 756-764
  • 2 de Dombal FT. Ulcerative colitis. Epidemiology and aetiology, course and prognosis. BMJ 1971; 1 (5750): 649-650
  • 3 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48 (04) 526-535
  • 4 Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91 (04) 854-862
  • 5 Söderlund S, Brandt L, Lapidus A. , et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136 (05) 1561-1567 , quiz 1818–1819
  • 6 Beaugerie L, Svrcek M, Seksik P. , et al; CESAME Study Group. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013; 145 (01) 166-175.e8
  • 7 Jess T, Loftus Jr EV, Velayos FS. , et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102 (04) 829-836
  • 8 Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143 (02) 375-81.e1 , quiz e13–e14
  • 9 Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol 2013; 108 (12) 1869-1876
  • 10 Velayos FS, Loftus Jr EV, Jess T. , et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130 (07) 1941-1949
  • 11 Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased?. World J Gastroenterol 2013; 19 (43) 7561-7568
  • 12 Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013; 19 (04) 789-799
  • 13 Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10 (06) 639-645
  • 14 Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2 (12) 1088-1095
  • 15 Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23 (08) 1097-1104
  • 16 Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012; 143 (02) 382-389
  • 17 Fumery M, Pineton de Chambrun G, Stefanescu C. , et al. Detection of dysplasia or cancer in 3.5% of patients with inflammatory bowel disease and colonic strictures. Clin Gastroenterol Hepatol 2015; 13 (10) 1770-1775
  • 18 Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008; 14 (25) 3937-3947
  • 19 Rutter MD, Saunders BP, Wilkinson KH. , et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130 (04) 1030-1038
  • 20 Jess T, Riis L, Vind I. , et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13 (04) 481-489
  • 21 Itzkowitz SH, Present DH. ; Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Inflamm Bowel Dis 2005; 11 (03) 314-321
  • 22 Rutter MD, Saunders BP, Wilkinson KH. , et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53 (12) 1813-1816
  • 23 Askling J, Dickman PW, Karlén P. , et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120 (06) 1356-1362
  • 24 Molodecky NA, Soon IS, Rabi DM. , et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142 (01) 46-54.e42 , quiz e30
  • 25 Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56 (01) 48-54
  • 26 Hofseth LJ, Saito S, Hussain SP. , et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 2003; 100 (01) 143-148
  • 27 Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448 (7152): 427-434
  • 28 Burmer GC, Rabinovitch PS, Haggitt RC. , et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992; 103 (05) 1602-1610
  • 29 Aust DE, Terdiman JP, Willenbucher RF. , et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 2002; 94 (05) 1421-1427
  • 30 Paradisi A, Maisse C, Coissieux M-M. , et al. Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proc Natl Acad Sci U S A 2009; 106 (40) 17146-17151
  • 31 Becker C, Fantini MC, Schramm C. , et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21 (04) 491-501
  • 32 Greten FR, Eckmann L, Greten TF. , et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118 (03) 285-296
  • 33 Pagès F, Berger A, Camus M. , et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353 (25) 2654-2666
  • 34 Erdman SE, Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer 2010; 127 (04) 768-779
  • 35 Deng L, Zhou J-F, Sellers RS. , et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol 2010; 176 (02) 952-967
  • 36 Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140 (06) 1807-1816
  • 37 Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut 2006; 55 (08) 1151-1155
  • 38 Gupta S. Trouble in Paris (classification): polyp morphology is in the eye of the beholder. Am J Gastroenterol 2015; 110 (01) 188-191
  • 39 Brenner H, Haug U, Arndt V, Stegmaier C, Altenhofen L, Hoffmeister M. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 2010; 138 (03) 870-876
  • 40 Schoen RE, Pinsky PF, Weissfeld JL. , et al; PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366 (25) 2345-2357
  • 41 Wang YR, Cangemi JR, Loftus Jr EV, Picco MF. Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol 2013; 108 (03) 444-449
  • 42 Rubin CE, Haggitt RC, Burmer GC. , et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103 (05) 1611-1620
  • 43 Iacucci M, Uraoka T, Fort Gasia M, Yahagi N. Novel diagnostic and therapeutic techniques for surveillance of dysplasia in patients with inflammatory bowel disease. Can J Gastroenterol Hepatol 2014; 28 (07) 361-370
  • 44 Efthymiou M, Allen PB, Taylor ACF. , et al. Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19 (10) 2132-2138
  • 45 Subramanian V, Ramappa V, Telakis E. , et al. Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease. Inflamm Bowel Dis 2013; 19 (02) 350-355
  • 46 Picco MF, Pasha S, Leighton JA. , et al. Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. Inflamm Bowel Dis 2013; 19 (09) 1913-1920
  • 47 Wu L, Li P, Wu J, Cao Y, Gao F. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Colorectal Dis 2012; 14 (04) 416-420
  • 48 Konijeti GG, Shrime MG, Ananthakrishnan AN, Chan AT. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc 2014; 79 (03) 455-465
  • 49 Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY. , et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol 2015; 110 (07) 1014-1021
  • 50 van den Broek FJ, Stokkers PC, Reitsma JB. , et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol 2014; 109 (05) 715-722
  • 51 Cairns SR, Scholefield JH, Steele RJ. , et al; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59 (05) 666-689
  • 52 Annese V, Daperno M, Rutter MD. , et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7 (12) 982-1018
  • 53 Kornbluth A, Sachar DB. ; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105 (03) 501-523 , quiz 524
  • 54 Farraye FA, Odze RD, Eaden J. , et al; AGA Institute Medical Position Panel on Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138 (02) 738-745
  • 55 Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. ; SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 2015; 81 (03) 489-501.e26
  • 56 Marion JF, Waye JD, Israel Y. , et al; Chromoendoscopy Study Group at Mount Sinai School of Medicine. Chromoendoscopy is more effective than standard colonoscopy in detecting dysplasia during long-term surveillance of patients with colitis. Clin Gastroenterol Hepatol 2016; 14 (05) 713-719
  • 57 Ignjatovic A, East JE, Subramanian V. , et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol 2012; 107 (06) 885-890
  • 58 van den Broek FJ, Fockens P, van Eeden S. , et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy 2011; 43 (02) 108-115
  • 59 Kiesslich R, Goetz M, Angus EM. , et al. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 2007; 133 (06) 1769-1778
  • 60 Kisiel JB, Yab TC, Nazer Hussain FT. , et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37 (05) 546-554
  • 61 Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 1994; 343 (8889): 71-74
  • 62 Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007; 25 (06) 657-668
  • 63 Navaneethan U, Jegadeesan R, Gutierrez NG. , et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohn's Colitis 2013; 7 (12) e684-e691
  • 64 Murphy J, Kalkbrenner KA, Pemberton JH. , et al. Dysplasia in ulcerative colitis as a predictor of unsuspected synchronous colorectal cancer. Dis Colon Rectum 2014; 57 (08) 993-998
  • 65 Venkatesh PG, Jegadeesan R, Gutierrez NG, Sanaka MR, Navaneethan U. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohn's Colitis 2013; 7 (12) 968-973
  • 66 Coviello LC, Stein SL. Surgical management of nonpolypoid colorectal lesions and strictures in colonic inflammatory bowel disease. Gastrointest Endosc Clin N Am 2014; 24 (03) 447-454
  • 67 Lutgens MW, Oldenburg B, Siersema PD. , et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer 2009; 101 (10) 1671-1675
  • 68 Provenzale D, Wong JB, Onken JE, Lipscomb J. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 1998; 93 (06) 872-880
  • 69 Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006; (02) CD000279
  • 70 Ananthakrishnan AN, Cagan A, Cai T. , et al. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2015; 13 (02) 322-329.e1
  • 71 Subramanian V, Logan RF. Chemoprevention of colorectal cancer in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2011; 25 (4-5): 593-606
  • 72 Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011; 106 (04) 731-736
  • 73 Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 2012; 107 (09) 1298-1304 , quiz 1297, 1305
  • 74 van Schaik FDM, van Oijen MGH, Smeets HM, van der Heijden GJMG, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012; 61 (02) 235-240
  • 75 Gong J, Zhu L, Guo Z. , et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One 2013; 8 (11) e81487
  • 76 Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013; 177 (11) 1296-1305
  • 77 Onizawa M, Nagaishi T, Kanai T. , et al. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2009; 296 (04) G850-G859
  • 78 Baars JE, Kuipers EJ, van Haastert M, Nicolaï JJ, Poen AC, van der Woude CJ. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol 2012; 47 (12) 1308-1322
  • 79 Osterman MT, Sandborn WJ, Colombel JF. , et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014; 146 (04) 941-949
  • 80 Søgaard KK, Cronin-Fenton DP, Pedersen L, Sørensen HT, Lash TL. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2008; 14 (04) 519-525
  • 81 Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol 2014; 7: 359-367
  • 82 Raaschou P, Simard JF, Neovius M, Askling J. ; Anti-Rheumatic Therapy in Sweden Study Group. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011; 63 (07) 1812-1822
  • 83 Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol 2014; 12 (11) 1793-1800.e1
  • 84 Brown ER, Charles KA, Hoare SA. , et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 2008; 19 (07) 1340-1346
  • 85 Jatoi A, Ritter HL, Dueck A. , et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010; 68 (02) 234-239
  • 86 Johnson DH, Taylor WR, Aboelsoud MM. , et al. DNA methylation and mutation of small colonic neoplasms in ulcerative colitis and Crohn's colitis: Implications for Surveillance. Inflamm Bowel Dis 2016; 22 (07) 1559-1567